Radioiodine therapy of thyroid cancer;Radiojodtherapie des schilddrüsenkarzinoms

Onkologe

Volumn 11, Issue 1, 2005, Pages 70-77

  Biermann, M ^a   Pixberg, M K ^a   Riemann, B ^a   Schuck, A ^a   Willich, N ^a   Schober, O ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Differentiated thyroid carcinoma; Metastases; Radioiodine therapy; Radiotherapy; Recurrence rates

Indexed keywords

RADIOACTIVE IODINE;

ARTICLE; AZOOSPERMIA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CERVICAL LYMPH NODE; FOLLOW UP; GASTRITIS; HUMAN; LEUKEMIA; LEUKOPENIA; LUNG FIBROSIS; PAPILLARY CARCINOMA; PRACTICE GUIDELINE; THROMBOCYTOPENIA; THYROID CANCER; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT INDICATION; TUMOR VOLUME; XEROSTOMIA;

EID: 13644259147     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-004-0814-0     Document Type: Article

References (35)

1. Bal C, Padhy AK, Jana S, Pant GS, Basu AK (1996) Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 77:2574-2580
2. Biermann M, Jürgens H, Schober O (2003) Maligne Schilddrü sentumoren. In: Reinhardt D (Hrsg) Therapie der Krankheiten im Kindes- und Jugendalter. Springer, Berlin Heidelberg Nerw York, S 734-737
3. Biermann M, Pixberg MK, Schuck A, Heinecke A, Köpcke W, Schmid KW, Dralle H, Willich N, Schober O, for the MSDS study group (2003) Multicenter Study Differentiated Thyroid Carcinoma (MSDS): Diminished acceptance of adjuvant external beam radiotherapy for differentiated thyroid carcinoma. Nuklearmedizin 42:244-250
4. Biermann M, Schober O (2003) Should High hTG levels in absence of iodine uptake be treated? Eur J Nucl Med 30:160-163
5. Biermann M, Pixberg M, Schuck A, Willich N, Heinecke A, Schober O (in press) External beam radiotherapy. In: Grünwald F (Hrsg) Thyroid cancer. Springer, Berlin Heidelberg Nerw York
6. Biermann M, Schober O (2002) Wie viele Hochrisikopatienten mit differenziertem Schilddrüsenkarzinom braucht ein "Tumorzentrum" pro Jahr? [Editorial]. Nuklearmedizin: 61-62
7. Bundesministerium für Umwelt Naturschutz und Reaktorsicherheit (2002) Verordnung über den Schutz vor Schäden durch ionisierende Strahlen (Strahlenschutzverordnung) vom 20.07.2001 mit Änderung vom 18.06.2002,
8. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, Busnardo B (1993) Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 34:1626-1631
9. Deutsche Krebsgesellschaft (2002) Maligne Schilddrüsentumoren. In: Kurzgefasste Interdisziplinäre Leitlinien 2002. Zuckschwerdt, 92-106
10. Dietlein M, Dressler J, Farahati J, Grunwald F, Leisner B, Moser E, Reiners C, Schicha H, Schober O (2004) Verfahrensanweisung zur Radiojodtherapie (RIT) beim differenzierten Schilddrüsenkarzinom (Version 2). Nuklearmedizin 43:115-120
11. Dietlein M, Dressler J, Eschner W, Lassmann M, Leisner B, Reiners C, Schicha H (2003) Verfahrensanweisung zum Radiojodtest (Version 2). Nuklearmedizin 42:116-119
12. Dietlein M, Dressler J, Eschner W, Leisner B, Reiners C, Schicha H (2003) Verfahrensanweisung für die lod-131-Ganzkörperszintigraphie beim differenzierten Schilddrüsenkarzinom (Version 2). Nuklearmedizin 42:123-125
13. Dietlein M, Schober O, Schicha H (2004) Über- oder Untertherapie des papillären Mikrokarzinoms der Schilddrüse? Überlegungen zur ablativen Radiojodtherapie. Nuklearmedizin 43:107-114
14. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA (2003) Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 44:451-456
15. Dottorini ME, Vignati A, Mazzucchelli L, Lomuscio G, Colombo L (1997) Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. J Nucl Med 38:669-675
16. Dralle H, Machens A, Brauckhoff M, Ukkat J, Sekulla C, Nguyen Thanh P, Lorenz K, Gimm O (2005) Surgery of thyroid cancer: Should the surgical guidelines be revised following the introduction of the new TNM classification? Onkologe 11 (im Druck)
17. Eichhorn W, Tabler H, Lippold R, Lochmann M, Schreckenberger M, Bartenstein P (2003) Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and after-care at the same institution. Thyroid 13:949-958
18. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC et al. (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885
19. Lerch H, Schober O, Kuwert T, Saur HB (1997) Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 15:2067-2075
20. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-28
21. MSDS study group, Biermann M, Pixberg MK, Schober O (2003) Effectiveness of I-131 therapy to ablate the thyroid remnant in 200 patients in the Multicenter Study Differentiated Thyroid carcinoma (MSDS) [Abstract]. J Nucl Med 44 [Suppl]:146
22. Reiners C (2003) Radiojodtherapie des differenzierten Schilddrüsenkarzinoms. Arzneimitteltherapie 2:39-47
23. Reiners C (2003) Diagnostik, Therapie und Nachsorge des Schilddrüsenkarzinoms. UNI-MED Verlag, Bremen
24. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein R, Smith A, Drucker WD (2001) Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:619-625
25. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, Ordonez NG (1992) The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714-720
26. Schlumberger M, Challeton C, DeVathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F (1996) Radioactive iodine treatment and external radiotherapy for lung and bone metastases of differentiated thyroid carcinoma. J Nucl Med 37:398-605
27. Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, Couette JE, Pinchera A, Parmentier C (1996) Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37:606-612
28. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C et al. (2004) Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 150:105-112
29. Schmid KW, Sheu S-Y, Tötsch M, Görges R, Bockisch A, Mann K (2005) Pathologie des Schilddrüsenkarzinoms. Onkologe 11: in press
30. Schuck A, Biermann M, Müller S, Schober O, Willich N (2001) Adjuvante Strahlentherapie beim lokal fortgeschrittenen Schildddrü senkarzinom. Nuklearmediziner 24:225-229
31. Schuck A, Biermann M, Schober O, Willich N (2005) Strahlentherapie des Schilddrüsenkarzinoms. Onkologe 11 (im Druck)
32. Simon D, Korber C, Krausch M, Segering J, Groth P, Gorges R, Grunwald F, Muller-Gartner HW, Schmutzler C, Kohrle J et al. (2002) Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med 29:775-782
33. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL (1998) Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Endocrinol Metab 83:4116-4122
34. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B et al. (1998) Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Int Med 129:622-627
35. Wittekind C, Meyer HJ, Bootz F (2002) TNM-Klassifikation maligner Tumoren. Springer, Berlin